menu
    • menu

    Company profile for Synaptogenix

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. Our experience and passion for novel drug therapies have enabled us to develop a pipeline that includes various treatment approaches for serious and difficult-to-treat diseases such as Alzheimer’s Disease, Fragile X Syndrome and N...
    Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. Our experience and passion for novel drug therapies have enabled us to develop a pipeline that includes various treatment approaches for serious and difficult-to-treat diseases such as Alzheimer’s Disease, Fragile X Syndrome and Niemann-Pick Type C.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SynaptogenixUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1185 Avenue of the Americas, 3rd Floor New York, NY 10036
    Telephone
    Telephone
    (973) 242-0005
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.synaptogen.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Synaptogenix Renamed TAO Synergies, Ticker Now TAOX
    Synaptogenix Renamed TAO Synergies, Ticker Now TAOX

    26 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/synaptogenix-announces-name-change-to-tao-synergies-and-new-ticker-symbol-taox-for-alignment-with-ai-focused-crypto-treasury-strategy-302491852.html

    PR NEWSWIRE
    26 Jun 2025
    Share Share
    Synaptogenix Begins TAO Staking, Appoints BitGo Custodian
    Synaptogenix Begins TAO Staking, Appoints BitGo Custodian

    24 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/synaptogenix-announces-initial-tao-acquisition-under-crypto-treasury-strategy-appoints-bitgo-as-custodian-and-commences-yield-generation-through-staking-302489342.html

    PR NEWSWIRE
    24 Jun 2025
    Share Share
    Synaptogenix Announces $5.0 Million Financing
    Synaptogenix Announces $5.0 Million Financing

    11 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/synaptogenix-announces-5-0-million-financing-302244690.html

    PR NEWSWIRE
    11 Sep 2024
    Share Share
    Synaptogenix Partners With LSU For Spinal Cord Injury Study
    Synaptogenix Partners With LSU For Spinal Cord Injury Study

    18 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/synaptogenix-announces-new-collaboration-with-lsu-health-new-orleans-for-study-of-proprietary-analogs-in-spinal-cord-injury-302200323.html

    PR NEWSWIRE
    18 Jul 2024
    Share Share
    Synaptogenix Gets FDA IND Authorization For Bryostatin-1 In Multiple Sclerosis
    Synaptogenix Gets FDA IND Authorization For Bryostatin-1 In Multiple Sclerosis

    26 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/synaptogenix-announces-fda-authorization-of-ind-application-for-clinical-trial-for-bryostatin-1-in-multiple-sclerosis-302182860.html

    PR NEWSWIRE
    26 Jun 2024
    Share Share
    Synaptogenix On DEA Cannabis Reclassification For Drug Discovery
    Synaptogenix On DEA Cannabis Reclassification For Drug Discovery

    07 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/synaptogenix-applauds-dea-proposal-to-reclassify-cannabis-and-shares-expected-benefits-to-cannasoul-for-cannabinoid-based-drug-discovery-302137968.html

    PR NEWSWIRE
    07 May 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search